Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done?

Trials

Volumn 15, Issue 1, 2014, Pages

  Wason, James M S ^a   Stecher, Lynne ^a,b   Mander, Adrian P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Family wise error rate; Multi arm clinical trial; Multiple test correction; Type I error rate

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL LITERATURE; SAMPLE SIZE; STUDY DESIGN; CONTROLLED CLINICAL TRIAL (TOPIC); METHODOLOGY; PROCEDURES; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

CONTROLLED CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84910039155     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-364     Document Type: Article

References (18)

1. Reed JC. Toward a New Era in cancer treatment: message from the new editor-in-chief. Mol Cancer Ther 2012, 11:1621-1622.
2. Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet 2014, 384:283-284. 10.1016/S0140-6736(14)61122-3, 25066148.
3. Stucke K, Kieser M. A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design. Statist Med 2012, 31:3579-3596.
4. Baron G, Perrodeau E, Boutron I, Ravaud P. Reporting of analyses from randomized controlled trials with multiple arms: a systematic review. BMC Med 2013, 11:84. 10.1186/1741-7015-11-84, 3621416, 23531230.
5. Dudoit S, Van Der Laan MJ. Multiple Testing Procedures with Applications to Genomics 2008, New York, NY: Springer, 494.
6. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46. 10.1097/00001648-199001000-00010, 2081237.
7. Bender R, Lange S. Adjusting for multiple testing - when and how?. J Clin Epidemiol 2001, 54:343-349. 10.1016/S0895-4356(00)00314-0, 11297884.
8. Feise RJ. Do multiple outcome measures require P-value adjustment?. BMC Med Res Methodol 2002, 2:8. 10.1186/1471-2288-2-8, 117123, 12069695.
9. Food and Drug administration Statistical Principles for Clinical Trials. E9 1998, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf, Food and Drug administration.
10. European medicines agency Points to Consider on Multiplicity Issues in Clinical Trials 2002, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf, European medicines agency.
11. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials 1999, Boca Raton, Fl: CRC Press.
12. Wason JMS, Jaki T, Stallard N. Planning multi-arm screening studies within the context of a drug development program. Statist Med 2013, 32:3424-3435.
13. Cook RJ, Farewell VT. Multiplicity considerations in the design and analysis of clinical trials. J Royal Stat Soc Ser A 1996, 159:93-110.
14. Hughes MD. Multiplicity in clinical trials. Encyclopedia Biostatistics 2005, 5:3446-3451.
15. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008, 14:4368-4371. 10.1158/1078-0432.CCR-08-0325, 18628449.
16. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials 2000, 21:527-539. 10.1016/S0197-2456(00)00106-9, 11146147.
17. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2012, Epublished.
18. Food and Drug administration Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics 2010, http://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf, Food and Drug administration.